Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.

Excessive accumulation of extracellular matrix (ECM) in the kidneys and epithelial-to-mesenchymal transition (EMT) of renal tubular epithelial cells contributes to the renal fibrosis that is associated with diabetic nephropathy. Histone deacetylase (HDAC) determines the acetylation status of histones and thereby controls the regulation of gene expression. This study examined the effect of HDAC inhibition on renal fibrosis induced by diabetes or transforming growth factor (TGF)-beta1 and determined the role of reactive oxygen species (ROS) as mediators of HDAC activation. In streptozotocin (STZ)-induced diabetic kidneys and TGF-beta1-treated normal rat kidney tubular epithelial cells (NRK52-E), we found that trichostatin A, a nonselective HDAC inhibitor, decreased mRNA and protein expressions of ECM components and prevented EMT. Valproic acid and class I-selective HDAC inhibitor SK-7041 also showed similar effects in NRK52-E cells. Among the six HDACs tested (HDAC-1 through -5 and HDAC-8), HDAC-2 activity significantly increased in the kidneys of STZ-induced diabetic rats and db/db mice and TGF-beta1-treated NRK52-E cells. Levels of mRNA expression of fibronectin and alpha-smooth muscle actin were decreased, whereas E-cadherin mRNA was increased when HDAC-2 was knocked down using RNA interference in NRK52-E cells. Interestingly, hydrogen peroxide increased HDAC-2 activity, and the treatment with an antioxidant, N-acetylcysteine, almost completely reduced TGF-beta1-induced activation of HDAC-2. These findings suggest that HDAC-2 plays an important role in the development of ECM accumulation and EMT in diabetic kidney and that ROS mediate TGF-beta1-induced activation of HDAC-2.

[1]  J. H. Oh,et al.  Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. , 1998, Kidney international.

[2]  Chun Li Zhang,et al.  Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy , 2002, Cell.

[3]  K. Sharma,et al.  The renal TGF-beta system in the db/db mouse model of diabetic nephropathy. , 1998, Experimental nephrology.

[4]  L. Gaudreau,et al.  High levels of oxidative stress globally inhibit gene transcription and histone acetylation. , 2006, DNA and cell biology.

[5]  B. Groner,et al.  The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 , 2003, The EMBO journal.

[6]  D. Schuppan,et al.  Trichostatin A, a Histone Deacetylase Inhibitor, Suppresses Collagen Synthesis and Prevents TGF-β1-Induced Fibrogenesis in Skin Fibroblasts , 2002 .

[7]  C. Nast,et al.  Expression of transforming growth factor-β isoforms in human glomerular diseases , 1996 .

[8]  J. Davie,et al.  The Transcriptional Repressor Sp3 Is Associated with CK2-phosphorylated Histone Deacetylase 2* , 2002, The Journal of Biological Chemistry.

[9]  I. G. Fantus,et al.  Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Y. Akai,et al.  Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. , 1996, Kidney international.

[11]  M. Bitzer,et al.  TGF-beta signaling in renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[12]  J. B. Kim,et al.  Hypoxia inhibits adipocyte differentiation in a HDAC-independent manner. , 2005, Biochemical and biophysical research communications.

[13]  Ping Zhu,et al.  The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 , 2003, The EMBO journal.

[14]  D. Schuppan,et al.  A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture , 1999, Hepatology.

[15]  K. Sharma,et al.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. Nast,et al.  Expression of transforming growth factor-beta isoforms in human glomerular diseases. , 1996, Kidney international.

[17]  Hong-Jian Zhu,et al.  Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. , 2002, Journal of the American Society of Nephrology : JASN.

[18]  Ivan V. Gregoretti,et al.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.

[19]  C. Allis,et al.  Histone methylation versus histone acetylation: new insights into epigenetic regulation. , 2001, Current opinion in cell biology.

[20]  C. Heldin,et al.  TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. , 1999, Journal of cell science.

[21]  E. Bottinger,et al.  TGF-β signaling in renal disease , 2002 .

[22]  K. H. Kim,et al.  Melatonin and taurine reduce early glomerulopathy in diabetic rats. , 1999, Free radical biology & medicine.

[23]  M. Steffes,et al.  Structural-functional relationships in diabetic nephropathy. , 1984, The Journal of clinical investigation.

[24]  K. Thai,et al.  Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy. , 1994, Kidney international.

[25]  T. Fujita,et al.  Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. , 2007, Journal of the American Society of Nephrology : JASN.

[26]  Jia Guo,et al.  Neutralization of TGF-β by Anti-TGF-β Antibody Attenuates Kidney Hypertrophy and the Enhanced Extracellular Matrix Gene Expression in STZ-Induced Diabetic Mice , 1996, Diabetes.

[27]  Jia Guo,et al.  The Renal TGF-β System in the db/db Mouse Model of Diabetic Nephropathy , 1998, Nephron Experimental Nephrology.

[28]  S. Berger,et al.  Histone modifications in transcriptional regulation. , 2002, Current opinion in genetics & development.

[29]  M. Jeong,et al.  Inhibition of Histone Deacetylation Blocks Cardiac Hypertrophy Induced by Angiotensin II Infusion and Aortic Banding , 2005, Circulation.

[30]  I. Adcock,et al.  Decreased histone deacetylase activity in chronic obstructive pulmonary disease. , 2005, The New England journal of medicine.

[31]  Y. Akai,et al.  Quantification of glomerular TGF-β1 mRNA in patients with diabetes mellitus , 1996 .

[32]  Sang Gyun Kim,et al.  Class I Histone Deacetylase-Selective Novel Synthetic Inhibitors Potently Inhibit Human Tumor Proliferation , 2004, Clinical Cancer Research.

[33]  H. Ha,et al.  Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells. , 2004, Kidney international.

[34]  Junwei Yang,et al.  Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. , 2001, The American journal of pathology.

[35]  S. Uh,et al.  Role of Reactive Oxygen Species in TGF-β1-Induced Mitogen-Activated Protein Kinase Activation and Epithelial-Mesenchymal Transition in Renal Tubular Epithelial Cells , 2005 .

[36]  P. London.  Injury , 1969, Definitions.

[37]  E. Ballestar,et al.  Snail Mediates E-Cadherin Repression by the Recruitment of the Sin3A/Histone Deacetylase 1 (HDAC1)/HDAC2 Complex , 2004, Molecular and Cellular Biology.

[38]  I. Morita,et al.  Protein kinase CK2 is a key activator of histone deacetylase in hypoxia‐associated tumors , 2008, International journal of cancer.

[39]  K. Sharma,et al.  Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. , 1994, The American journal of physiology.

[40]  E Ruoslahti,et al.  Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  E. Olson,et al.  Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy , 2006, Circulation.

[42]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[43]  P. Wade.  Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. , 2001, Human molecular genetics.

[44]  Y. Tomino,et al.  mRNA Expression of Growth Factors in Glomeruli From Diabetic Rats , 1993, Diabetes.

[45]  E. Lobenhofer,et al.  Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. Brenner,et al.  Hepatitis C virus–induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity , 2008, Hepatology.

[47]  K. Thai,et al.  Expression of transforming growth factor-β1 during diabetic renal hypertrophy , 1994 .

[48]  J. Meinkoth,et al.  Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation , 2004, Cancer Research.

[49]  J. Y. Lee,et al.  Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. , 2003, Journal of medicinal chemistry.

[50]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[51]  E. Seto,et al.  Regulation of Histone Deacetylase 2 by Protein Kinase CK2* , 2002, The Journal of Biological Chemistry.